Innovent Biologics, Inc. (OTCMKTS:IVBXF) Sees Significant Increase in Short Interest

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 526,150 shares, a growth of 88.4% from the January 29th total of 279,298 shares. Based on an average daily volume of 4,888 shares, the short-interest ratio is presently 107.6 days. Based on an average daily volume of 4,888 shares, the short-interest ratio is presently 107.6 days.

Innovent Biologics Price Performance

IVBXF opened at $11.30 on Friday. Innovent Biologics has a 1 year low of $4.69 and a 1 year high of $15.12. The firm has a 50 day moving average price of $10.77 and a 200 day moving average price of $11.51.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).